title: Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
abstract: Therapies for central nervous system (CNS) diseases remain an unmet medical need. This is largely due to multiple unknown disease-modifying genes and pathways. Systems biology through network modeling has shown promise in discovering novel therapeutic targets, deciphering disease mechanisms, and suggesting drug repurposing opportunities. In this article we cover current progress in systems biology and its role, applications, and challenges in the pharmaceutical industry. We also outline a practical strategy to infer drug repositioning candidates for rare CNS diseases by describing Multiple Level Network Modeling (MLNM) analysis.
authors: Informatics and Structure Biology, R&D China, GlaxoSmithKline, Shanghai, China. Hongkang.k.mei@gsk.com
authors: Hongkang
authors: H
authors: Mei
authors: Tian
authors: T
authors: Xia
authors: Gang
authors: G
authors: Feng
authors: Jason
authors: J
authors: Zhu
authors: Simon M
authors: SM
authors: Lin
authors: Yang
authors: Y
authors: Qiu
mesh_terms: D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D015195:Drug Design; D004345:Drug Industry / Q000379:methods; D058492:Drug Repositioning; D006801:Humans; D008962:Models, Theoretical; D058990:Molecular Targeted Therapy; D035583:Rare Diseases / Q000188:drug therapy / Q000503:physiopathology; D049490:Systems Biology / Q000379:methods*
chemical_list: D002491:Central Nervous System Agents